HomeCONGRESS

CONGRESS

View Category
Day 3

INHERIT: Losartan in hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy is the most common hereditary cardiac pathology (1/1500) and is associated to heart failure, angina,...
solaci -
Learn More
Day 3

Reducing antibiotic prophylaxis: impact on endocarditis incidence.

Antibiotic prophylaxis before dental procedures has been the gold standard in preventing infective endocarditis, despite the lack...
solaci -
Learn More
Day 3

Atenolol vs. Losartan in children and young adults with Marfan syndrome

Article Aortic root dissection is the main cause of mortality in Marfan syndrome. Recent studies suggest that losartan...
solaci -
Learn More
Day 4

LIFELINE STEMI ACCELERATOR TRIAL: Improving the duration of treatment of AMI can save even more lives

Matthew W Sherwood2014-11-20
solaci -
Learn More
Day 4

AVOID: Randomized controlled trial of oxygen therapy in AMI with ST-segment elevation: Air versus oxygen in myocardial infarction

Dion Stub2014-11-20
solaci -
Learn More
Day 4

EVOLVE II TRIAL: SYNERGY everolimus-eluting stent is not inferior to Promus Element

Dean J. Kereiakes2014-11-20
solaci -
Learn More
Day 4

Long-term outcome of a biodegradable polymer compared with durable polymers in drug eluting and conventional stents – Main results of a prospective randomized study

ArticleChristoph A Kaiser2014-11-20
solaci -
Learn More
Day 1

PEGASUS-TIMI 54: Ticagrelor plus ASA in stable patients

This double-blind study included 21162 patients with a history of acute myocardial infarction randomized to ticagrelor 90...
solaci -
Learn More